The UK Health Security Agency (UKHSA) has reported a 22% increase in Lyme disease cases in England, with 1,168 confirmed cases in 2025 compared to 959 in 2024. This rise is attributed to various factors, including increased awareness and changes in outdoor activity. Lyme disease, caused by the Borrelia burgdorferi bacteria, is transmitted through tick bites, and symptoms can include a characteristic bullseye rash, fever, and joint pain. Experts, including Dr. Claire Gordon of UKHSA, emphasize the importance of prevention strategies such as using repellents and wearing protective clothing. Despite the growing number of cases, the development of human vaccines has faced hurdles. The previous vaccine, LYMErix, was withdrawn in 2002 due to low demand and safety concerns. Currently, new vaccines are under development, including an mRNA vaccine from Moderna and another from Pfizer and Valneva, both aiming to improve efficacy while minimizing side effects. Julia Knight from Lyme Disease UK highlights the potential for increased vaccine adoption, but notes ongoing vaccine hesitancy could impact public acceptance. As research continues, the focus remains on prevention and advancing treatment options for Lyme disease.